Policy | August 16, 2021
India restricts export of Rapid Antigen Test Kits used to detect Covid 19
The notification implies that any export of Rapid Antigen Kit will require a licence or permission from DGFT
The notification implies that any export of Rapid Antigen Kit will require a licence or permission from DGFT
This is the first of its kind vaccine for Covid 19 to get the go-ahead
It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The company is eligible for 12 months exclusivity from launch
The company has strong product launches both in India and overseas
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Subscribe To Our Newsletter & Stay Updated
